This content is machine translated Oral JAK-i in atopic dermatitis Benefits and risks: What does the current data say? Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of...…
View Post 6 min This content is machine translated Atopic eczema EuroGuiDerm guideline – overview of current recommendations for system therapy Recently, there have been significant advances in the treatment of atopic dermatitis, including several new systemic therapeutic options overcoming regulatory hurdles. This has also been incorporated into the EuroGuiDerm guideline…
View Post 16 min This content is machine translated Moderate to severe atopic dermatitis Changing therapeutic landscape – broad arsenal of treatment options New therapies in the form of specific antibodies and “small molecules” have ushered in a new era. Biologics intervene in the inflammatory process of atopic dermatitis by targeting individual cytokines.… CME-Test
View Post 3 min This content is machine translated Atopic dermatitis: JAK inhibitors Baricitinib combined with topical steroids achieves high patient benefit When topical steroid therapy alone is not sufficiently effective, patients with atopic dermatitis may benefit greatly from the additional use of the JAK inhibitor baricitinib. This is shown, among other…
View Post 4 min This content is machine translated Atopic dermatitis Long-term efficacy of baricitinib proven In adult patients with moderate to severe atopic dermatitis, long-term therapy with the JAK inhibitor baricitinib maintained improvements achieved after 16 weeks for 68 weeks, new data show. A pooled…
